Proprietary recombinant human interferon beta-1b (NU100) in RRMS study launched
Nuron Biotech Inc., a specialty biologics and vaccines company, today announced the initiation of a randomized, double-blind, placebo-controlled, pivotal Phase 3 study to evaluate the safety and efficacy of NU100 in patients with relapsing remitting multiple sclerosis (RRMS).
NU100 is a proprietary recombinant human interferon beta-1b (IFN beta-1b) being developed as a new molecular entity. The product is an essentially aggregate-free liquid formulation produced utilizing an advanced processing technology.
"Nuron Biotech has assembled a proven management team, established a quality pipeline in multiple disease areas and worked very diligently to advance our lead compound into Phase 3," said Shankar Musunuri, Ph.D., MBA, Chief Executive Officer and Founder of Nuron Biotech. "We are making excellent progress toward our goal of bringing innovative and improved biologics to markets in need."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2872